MEK

Mitogen-activated protein kinase kinase; MAPKK; MAP2K

MEK

MEK Isoform Specific Products:

MEK Isoform Comparison

MEK Related Products (144)
Antibodies (9)
MEK Isoform Comparison

By Effects:	Inhibitors (130) Degrader (1) Antagonists (2) Activators (3)

Cat. No.	Product Name	Effect	Purity	Chemical Structure

HY-10999

Trametinib	Inhibitor	99.96%
Trametinib (GSK1120212; JTP-74057) is an orally active MEK inhibitor that inhibits MEK1 and MEK2 with IC₅₀s of about 2 nM. Trametinib activates autophagy and induces apoptosis.

HY-10254

Mirdametinib	Inhibitor	99.95%
Mirdametinib (PD0325901) is an orally active, selective and non-ATP-competitive MEK inhibitor with an IC₅₀ of 0.33 nM. Mirdametinib exhibits a K_i^app of 1 nM against activated MEK1 and MEK2. Mirdametinib suppresses the expression of p-ERK1/2 and induces apoptosis. Mirdametinib has anti-cancer activity for a broad spectrum of human tumor xenografts.

HY-12028

PD98059	Inhibitor	99.96%
PD98059 is a potent and selective MEK inhibitor with an IC₅₀ of 5 µM. PD98059 binds to the inactive form of MEK, thereby preventing the activation of MEK1 (IC₅₀ of 2-7 µM) and MEK2 (IC₅₀ of 50 µM) by upstream kinases. PD98059 is a ERK1/2 signaling inhibitor. PD98059 is a ligand for the aryl hydrocarbon receptor (AHR), and suppresses TCDD binding (IC₅₀ of 4 μM) and AHR transformation (IC₅₀ of 1 μM). PD98059 also inhibits Mycobacterium bovis Bacillus CalmetteGuerin (BCG)-induced autophagy.

HY-12031A

U0126	Inhibitor	98.45%
U0126 is a potent, non-ATP competitive and selective MEK1 and MEK2 inhibitor, with IC₅₀s of 72 nM and 58 nM, respectively. U0126 is an autophagy and mitophagy inhibitor.

HY-50706

Selumetinib	Inhibitor	99.87%
Selumetinib (AZD6244) is selective, non-ATP-competitive oral MEK1/2 inhibitor, with an IC₅₀ of 14 nM for MEK1. Selumetinib (AZD6244) inhibits ERK1/2 phosphorylation.

HY-402361

TERT activator-1		99.50%
TERT activator-1 is a small molecule activator of telomerase reverse transcriptase (TERT). TERT activator-1 promotes TERT transcription through the MEK/ERK/AP-1 signaling cascade. TERT activator-1 promotes adult neurogenesis and enhances neuromuscular function. TERT activator-1 reduces cellular senescence and systemic inflammation in aged mice, and can be used in the study of aging.

HY-172415

Atebimetinib	Inhibitor
Atebimetinib is an inhibitor for MEK tyrosine kinase and exhibits antineoplastic activity.

HY-169407

AKT-IN-24	Inhibitor
KT-IN-24 (Compound M17) is a AKT allosteric inhibitor with anti-tumor activity. KT-IN-24 can target the AKT/mTOR and MEK/ERK signaling pathways and inhibit epithelial-mesenchymal transition, which has a synergistic suppressive effect on TNBC, promoting cell apoptosis while inhibiting proliferation and migration when used in combination with Trametinib (HY-10999).

HY-12031

U0126-EtOH	Inhibitor	99.41%
U0126 (U0126-EtOH) is a potent, non-ATP competitive and selective MEK1 and MEK2 inhibitor, with IC₅₀s of 72 nM and 58 nM, respectively. U0126 is an autophagy and mitophagy inhibitor.

HY-13064

Cobimetinib	Inhibitor	99.81%
Cobimetinib (GDC-0973, RG7420) is a potent, selective and oral MEK1 inhibitor with an IC₅₀ of 4.2 nM for MEK1.

HY-15202

Binimetinib	Inhibitor	99.28%
Binimetinib (MEK162) is an oral and selective MEK1/2 inhibitor. Binimetinib (MEK162) inhibits MEK with an IC₅₀ of 12 nM.

HY-108635

C16-PAF	Activator	99.85%
C16-PAF (PAF (C16)), a phospholipid mediator, is a platelet-activating factor and ligand for PAF G-protein-coupled receptor (PAFR). C16-PAF exhibits anti-apoptotic effect and inhibits caspase-dependent death by activating the PAFR. C16-PAF is a potent MAPK and MEK/ERK activator. C16-PAF induces increased vascular permeability.

HY-N0776

Isorhamnetin	Inhibitor	99.94%
Isorhamnetin is a flavonoid compound extracted from the Chinese herb Hippophae rhamnoides L.. Isorhamnetin suppresses skin cancer through direct inhibition of MEK1 and PI3K.

HY-18652

Avutometinib	Inhibitor	99.02%
Avutometinib (Ro 5126766) is a first-in-class dual MEK/RAF inhibitor that allosterically inhibits BRAF^V600E, CRAF, MEK, and BRAF (IC₅₀: 8.2, 56, 160 nM, and 190 nM, respectively).

HY-B0185

Lidocaine	Inhibitor	99.96%
Lidocaine (Lignocaine) inhibits sodium channels involving complex voltage and using dependence. Lidocaine decreases growth, migration and invasion of gastric carcinoma cells via up-regulating miR-145 expression and further inactivation of MEK/ERK and NF-κB signaling pathways. Lidocaine is an amide derivative and has potential for the research of ventricular arrhythmia.

HY-10999A

Trametinib (DMSO solvate)	Inhibitor	99.56%
Trametinib (DMSO solvate) (GSK-1120212 (DMSO solvate);JTP-74057 (DMSO solvate)) is an orally active MEK inhibitor that inhibits MEK1 and MEK2 with IC₅₀s of about 2 nM. Trametinib (DMSO solvate) activates autophagy and induces apoptosis.

HY-19700

trans-Zeatin	Inhibitor	99.83%
trans-Zeatin is a plant cytokinin, which plays an important role in cell growth, differentiation, and division; trans-Zeatin also inhibits UV-induced MEK/ERK activation.

HY-158115

NST-628	Inhibitor	98.61%
NST-628 is a brain-permeable MAPK pathway molecule glue that inhibits RAF phosphorylation and MEK activation. NST-628 also binds RAF and prevents the formation of BRAF-CRAF and BRAF-ARAF heterodimers, effectively inhibiting the RAS-MAPK pathway. NST-628 inhibits RAS- and RAF-driven cancers and demonstrated potent inhibition in mutant KRAS, NRAS, BRAF class II/III, and NF1-mutant tumors.

HY-50295

CI-1040	Inhibitor	99.91%
CI-1040 (PD 184352) is an orally active, highly specific, small-molecule inhibitor of MEK with an IC₅₀ of 17 nM for MEK1.

HY-12042

Pimasertib	Inhibitor	99.88%
Pimasertib (AS703026) is a highly selective, ATP non-competitive allosteric orally available MEK1/2 inhibitor.

Trametinib	MEK1, IC₅₀: 2 nM	MEK2, IC₅₀: 2 nM			99.96%
Mirdametinib	MEK1, Ki: 1 nM	MEK2, Ki: 1 nM		MEK, IC₅₀: 0.33 nM	99.95%
PD98059	MEK1, IC₅₀: 2-7 μM	MEK2, IC₅₀: 50 μM			99.96%
U0126	MEK1, IC₅₀: 70 nM	MEK2, IC₅₀: 60 nM			98.45%
Selumetinib	MEK1, IC₅₀: 14 nM			MEK, IC₅₀: 12 nM	99.87%
TERT activator-1	MEK1	MEK2			99.50%
U0126-EtOH	MEK1, IC₅₀: 70 nM	MEK2, IC₅₀: 60 nM			99.41%
Cobimetinib	MEK1, IC₅₀: 4.2 nM				99.81%
Binimetinib				MEK, IC₅₀: 12 nM	99.28%
C16-PAF				MEK	99.85%
Isorhamnetin	MEK1				99.94%
Avutometinib				MEK, IC₅₀: 160 nM	99.02%
Lidocaine				MEK	99.96%
Trametinib (DMSO solvate)	MEK1, IC₅₀: 2 nM	MEK2, IC₅₀: 2 nM			99.56%
trans-Zeatin				MEK	99.83%
CI-1040	MEK1, IC₅₀: 17 nM				99.91%
Pimasertib	MEK1	MEK2			99.88%
Lixisenatide	MEK1	MEK2			99.93%
GDC-0623	MEK1, Ki: 0.13 nM (+ATP)				98.74%
Lidocaine hydrochloride				MEK	99.84%
BIX02189			MEK5, IC₅₀: 1.5 nM		99.99%
Trametiglue	MEK1	MEK2			98.58%
Refametinib	MEK1, IC₅₀: 19 nM	MEK2, IC₅₀: 47 nM			99.82%
APS-2-79	MEK1				99.38%
TAK-733				MEK, IC₅₀: 3.2 nM	98.31%
Lidocaine (Standard)				MEK	99.85%
AZD8330	MEK1, IC₅₀: 7 nM	MEK2, IC₅₀: 7 nM			99.14%
SL327	MEK1, IC₅₀: 180 nM	MEK2, IC₅₀: 220 nM			99.57%
MS432	MEK1, DC₅₀: 31 nM (in HT29 cells) MEK1, DC₅₀: 31 nM (in SK-MEL-28 cells)	MEK2, DC₅₀: 17 nM (in HT29 cells) MEK2, DC₅₀: 9.3 nM (in SK-MEL-28 cells)			99.78%
RGB-286638	MEK1, IC₅₀: 54 nM				99.70%
Azelnidipine	MEK1	MEK2			99.66%
MAP855	MEK1, IC₅₀: 3 nM				98.48%
BI-847325		MEK2, IC₅₀: 4 nM			98.15%
Tunlametinib	MEK1	MEK2			98.25%
RO4987655	MEK1, IC₅₀: 5.2 nM	MEK2, IC₅₀: 5.2 nM			99.21%
BIX02188			MEK5, IC₅₀: 4.3 nM		99.85%
GW284543			MEK5		99.94%
Zapnometinib				MEK, IC₅₀: 5.7 nM	99.85%
PD318088	MEK1	MEK2			99.91%
Cobimetinib hemifumarate	MEK1, IC₅₀: 4.2 nM				99.73%
RGB-286638 free base	MEK1, IC₅₀: 54 nM				98.07%
PD 198306				MEK	99.75%
Nedometinib	MEK1, IC₅₀: 135 nM				98.25%
MEK inhibitor				MEK	98.35%
PD184161				MEK, IC₅₀: 10-100 nM	98.08%
Lidocaine hydrochloride hydrate				MEK	99.90%
MEK-IN-6				MEK	98.69%
PD0325901-O-C2-dioxolane	MEK1	MEK2			98.62%
PD-334581	MEK1				99.72%
Hypothemycin	MEK1, Ki: 17 nM	MEK2, Ki: 38 nM			≥98.0%
E6201	MEK1, IC₅₀: 5.2 nM
Refametinib (R enantiomer)				MEK, EC₅₀: 2-15 nM
Balamapimod				MEK	99.47%
CHMFL-EGFR-202	MEK1, IC₅₀: 161 nM				99.75%
APS-2-79 hydrochloride	MEK1
GW284543 hydrochloride			MEK5
MEK/RAF-IN-1	MEK1, IC₅₀: 28 nM
MEK/PI3K-IN-2	MEK1, IC₅₀: 352 ± 2 nM
MEK/PI3K-IN-1	MEK1, IC₅₀: 124 ± 11 nM
Isorhamnetin (Standard)	MEK1
MEK1-IN-1	MEK1, : 10.29 nM
MEK-IN-6 hydrate				MEK
MEK-IN-1				MEK

Name
Email *

	Sorry, but the email address you supplied was invalid.

MEK

MEK

MEK Isoform Specific Products:

MEK Isoform Specific Products:

MEK Related Products (144)

Antibodies (9)

MEK Isoform Comparison

MEK Related Products (144):